A novel prognostic marker for cardiovascular risk in individuals with type 2 diabetes (T2D) has been identified by the IMMEDIAB team – Immunity and Metabolism in Diabetes, led by Nicolas Venteclef at INEM.
This breakthrough, the result of collective and collaborative efforts, positions our researchers at the forefront of a significant scientific leap.
The study, involving phenotypic, transcriptomic, and metabolomic analyses across three cohorts of T2D patients - Angiosafe, GLUTADIAB, and SURDIAGENE - reveals a correlation between the number of circulating monocytes and an increased risk of cardiovascular events such as stroke or myocardial infarction over a decade.
Published in Circulation Research and highlighted in an INSERM press release, this work is a substantial step forward in understanding, assessing, and preventing cardiovascular incidents in type 2 diabetic patients.
With a patent already filed for this discovery and the ongoing development of a cutting-edge electronic sensor for measuring circulating monocytes from a single drop of blood, this innovation promises to transform patient care.
The potential impact of this research on the cardiovascular health of millions of people with type 2 diabetes is immense, ushering in new and promising horizons in the medical field.
To read the press release: inserm press
To learn more about the study: Circulation Research